Hemophilia
We recommend
![kloub](https://www.prolekare.cz/media/cache/resolve/article_list_item_large/media/image/3278082490f5c3c59ea5c0a1f74b480f.jpg)
Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment
With the development of new treatment options for hemophilia, there has also been progress in methods for monitoring hemophilic arthropathy and identifying it in its early stages. In addition to classical X-rays, clinical scoring systems, and the gold standard of magnetic resonance imaging (MRI), the so-called POCUS – point-of-care ultrasound – has emerged as a quick and reliable method for assessing joint health. Potential biomarkers for osteochondral damage and synovial proliferation specific to hemophilia or for detecting joint…
![hemofilie](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/db137e3dabedd3e10e476a444d7d3b01.jpg)
Collagen Turnover as a Biomarker of Hemophilia Treatment Efficacy
Over the past decades, hemophilia treatment has made significant progress—from factor therapy to…
![krev_zkumavky](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/b2dcdeb944279f847600d40fe76e3d76.jpg)
FEIBA in Real Clinical Practice – Fresh Data from the Observational Study FEIBA GO
FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term…
Articles on this topic
![Osteopenie kost](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/e49d06afe4ab060aa4981bb197ed7661.jpg)
Bone density in hemophiliacs − known and less-known risk factors
Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these…
![čas a krev](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/ad623cce910137cb0cc0fbfd30ffa6ad.jpg)
Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
The famous slogan of neurologists in connection with strokes – 'Time is brain!' – can be…
![lékař radost malý kluk a matka](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/122ce228434f2892f67bd954cf596552.jpg)
Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of…
![starší muž na neurologii](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/b5cb45ca1599b4cd6dea9ffa98d42d55.jpg)
Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of…
![medicínská studie 2](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/7e4292742ca31de9d93837076468c404.jpg)
Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the…
![farmakologie farmakokinetika](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/25f0ae60d452e6e3e0c6e64f2c69ba61.jpg)
Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were…
![farmakokinetický protokol krev zkumavky](https://www.prolekare.cz/media/cache/resolve/article_list_item_small/media/image/da84e86e52a486294c7a90546498b977.jpg)
Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple…
1
2
Subscribe
E-courses on this topic
Most read on this topic
- Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
- Current Expert Consensus on Prophylaxis of Individuals with Mild and Moderate Hemophilia A: These Patients Also Deserve Better Care
- Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
- Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
- Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
- Dosing and Consumption of rFVIII Products with Extended Half-life in Patients with Hemophilia A in Real-World Practice
Journal on this topic
Related topic
Interesting links